FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects. The insect cell-baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus-insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for expresSF cell line used for the manufacturing of FluBlok. In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biologicals.2009.02.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The peculiar characteristics and advancement in diagnostic methodologies of influenza A virus.
Front Microbiol
January 2025
CAS Key Laboratory of Molecular Virology and Immunology, Institutional Center for Shared Technologies and Facilities, Pathogen Discovery and Big Data Platform, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.
Influenza A virus (IAV) is a significant public health concern, causing seasonal outbreaks and occasional pandemics. These outbreaks result from changes in the virus's surface proteins which include hemagglutinin and neuraminidase. Influenza A virus has a vast reservoir, including wild birds, pigs, horses, domestic and marine animals.
View Article and Find Full Text PDFRevealing trends in measles immunity during periods of varying measles circulation in Madagascar.
Am J Epidemiol
January 2025
Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA.
Estimating the durability of immunity from vaccination is complicated by unreported re-vaccination, and unobserved natural infection or reexposure, which could result in overestimation of protection longevity. We tested serial cross-sectional serum samples from 2005 to 2015 (N=2,530) for IgG to examine measles seroprevalence, spatiotemporal patterns of titers across regions and antibody dynamics among children aged 1-9 years who grew up during varying measles circulation in Madagascar under a one-dose vaccination schedule. We found that measles seroprevalence has generally decreased over this time period.
View Article and Find Full Text PDFAssociation between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine.
Vaccine
January 2025
Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety, Shenzhen campus of Sun Yat-sen University, Shenzhen 518107, China; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China; Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510080, China. Electronic address:
Objective: Seasonal influenza vaccine is effective to reduce the risk of hospitalization and death in vulnerable older persons, but the coverage of influenza vaccine remains low in these population in China. This study thus aimed to investigate how adults' vaccine literacy affects their intention to recommend influenza vaccination to older family members in China.
Methods: A cross-sectional survey was performed in China during October 7 to 16, 2023 through a web-based questionnaire.
Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case-control study.
Eur J Public Health
January 2025
Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
Marketing authorization holders of vaccines typically need to report brand-specific vaccine effectiveness (VE) to the regulatory authorities as part of their regulatory obligations. COVIDRIVE (now id. DRIVE) is a European public-private partnership for respiratory pathogen surveillance and studies of brand-specific VE with long-term follow-up.
View Article and Find Full Text PDFDistinct response patterns of endothelial markers to the BNT162b2 mRNA COVID-19 booster vaccine are associated with the spike-specific IgG antibody production.
Front Immunol
January 2025
Faculty of Medicine, University of Castilla-La Mancha, Albacete, Spain.
Introduction: Despite the efficacy and safety of SARS-CoV-2 vaccines, inflammatory and/or thrombotic episodes have been reported. Since the impact of COVID-19 vaccines on the endothelium remains uncertain, our objective was to assess endothelial activation status before and 90 days after the third dose of the BNT162b2 mRNA COVID-19 vaccine.
Methods: A prospective longitudinal study was conducted at University General Hospital of Albacete, involving 38 healthy health-care workers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!